First XPS™ to southern Europe and continued success in the US
The second XPS™ in Europe has been bought by a clinic in Italy and another XPS™ contract has been signed in the US. It is estimated that delivery of the XPS™ will take place in March and early April.
XVIVO Perfusion’s XPS™ and STEEN Solution™ have already been approved, as only medical device, in the USA for evaluation of marginal lungs before lung transplantation. The CE mark obtained last year has enabled the European market to perform evaluations of lungs in a closed system with the XPS™ and STEEN Solution™. Leading clinics in the USA using XPS™ have obtained good clinical results and the decision to buy an XPS™ was taken by the Italian clinic after a visit to the USA, where they received XPS™ training.
The launch in the US continues and yet another clinic in the United States has signed a XPS™ contract. Including the last two contracts, 16 clinics in the United States and three clinics outside the US have access to the XPS™ system that facilitates lung evaluation using STEEN Solution™.
“It is very exciting that EVLP with XPS™ and STEEN Solution™ will be used for clinical lung transplants in Italy and that the US launch is showing continued progress. The company sees a continued high interest from American and European clinics to set up XVIVOs XPS ™ system to facilitate lung evaluation using STEEN Solution™”, says Magnus Nilsson, CEO of XVIVO Perfusion.
March 27, 2015
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on March 27, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se .
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com